Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for ...

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average ( ^DJI 0.78%) had just a ...

Palantir stock rebounds, sales of Eli Lilly’s blockbuster GLP-1 medicines miss estimates, and Boeing’s 2024 deliveries fall ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...

"Eli Lilly Cuts 4Q Sales Outlook After Sluggish Growth for Incretin Drugs," published at 10:06 a.m. ET, incorrectly said the outlook was around $400 below the low end of its last estimated range ...

Drops for Eli Lilly and other influential companies are weighing on U.S. indexes Tuesday, even though most of the market is ...

Eli Lilly cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company sees healthy growth in 2025 due to the success ...

The Dow Jones Industrial Average rose on Tuesday as traders weighed ... they had for obesity drugs may not materialize as hoped. Lilly shares, which were approaching a trillion-dollar market ...

Shares of Eli Lilly & Co. LLY sank 0.30% to $797.48 Monday, on what proved to be an all-around great trading session for the ...

though drops for Eli Lilly and other influential stocks kept indexes in check. The S&P 500 rose 0.1% as three out of every four stocks in the index climbed. The Dow Jones Industrial Average added ...